Stockhouse

PDI, Inc. Subsidiary Interpace Diagnostics Enters Molecular Diagnostics Market with Thyroid and Pancreatic Cancer Test Portfolio Acquisition

PARSIPPANY, N.J., Aug. 13, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, today announced that its Interpace Diagnostics subsidiary has entered the ...
Medindia

PDI, Inc. and Transgenomic, Inc. Partner to Commercialize Personalized Medicine Molecular Diagnostic Test

PDI, Inc. (Nasdaq: PDII) and Transgenomic, Inc. (OTCBB: TBIO), today announced the signing of a U.S. collaboration agreement to commercialize CardioPredict™, a molecular diagnostic test developed by ...
Finanznachrichten

PDI, Inc. Subsidiary Interpace Diagnostics Enters Molecular Diagnostics Market with Thyroid and Pancreatic Cancer Test Portfolio Acquisition

PARSIPPANY, N.J., Aug. 13, 2014 /PRNewswire/ --PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, today announced that its Interpace Diagnostics subsidiary has entered the ...